Compounded Semaglutide Shelf Life Once Opened

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide remains viable for approximately 28 days after opening when stored at refrigerator temperature (2–8°C). This timeline assumes proper handling, sealed pen design, and adherence to pharmacy-specific storage instructions. Stability varies slightly between compounding facilities based on formulation and delivery mechanism.

Knowing your medication's shelf life after opening is critical for treatment adherence and cost management. Unlike branded preparations, compounded semaglutide requires careful attention to storage conditions and expiration protocols. PlexusDx emphasizes precision in medication handling as part of a broader personalized wellness approach.

Temperature and Storage Conditions That Preserve Stability

Compounded semaglutide injections must be stored at 2–8°C (refrigerator temperature) once opened. Temperatures above 8°C or exposure to light can degrade the active peptide. Room-temperature storage dramatically reduces shelf life to 2–7 days depending on ambient conditions.

Never freeze compounded semaglutide after opening, as freezing denatures the peptide structure and renders the medication ineffective. Store pens upright in the refrigerator away from freezer compartments. If accidentally frozen, discard immediately—do not thaw and reuse.

Stability Timeline: What Happens Day by Day After Opening

Compounded semaglutide undergoes gradual potency loss even under ideal storage. The 28-day window represents acceptable stability for clinical efficacy, though potency may decline slightly after day 14. Your pharmacy's specific formulation method influences this timeline; always follow your dispensing pharmacy's written guidance.

Storage Phase	Temperature & Conditions	Recommended Use Window	Potency Expectation
Days 1–7 (Optimal)	2–8°C, sealed pen, upright position	Full efficacy period; use freely	99–100% of labeled potency
Days 8–14 (Good)	2–8°C, minimal light exposure	Reliable efficacy; recommended use	95–99% of labeled potency
Days 15–28 (Acceptable)	2–8°C, protected from light	May use if needed; monitor response	85–95% of labeled potency
Beyond Day 28	Any condition	Discard; potency unreliable	<85% of labeled potency; unsafe

Factors That Accelerate Degradation and Reduce Shelf Life

Light exposure is one of the most common causes of premature semaglutide breakdown. Store pens in opaque, light-blocking containers within the refrigerator. Repeated temperature fluctuations—opening and closing the fridge frequently—also degrade the peptide over time.

Contamination risk increases after opening. Never allow the needle or cartridge contact surfaces to touch non-sterile items. If a pen is dropped or suspected of contamination, discard it immediately even if within the 28-day window. Injectable peptides are vulnerable to bacterial growth once the sealed environment is breached.

Personalized Considerations: Genetic Factors and Treatment Continuity

Individual metabolic responses to semaglutide vary partly due to genetic variation in GLP-1 receptor and metabolic pathways. While genetics do not directly affect how long your medication stays stable, they influence how quickly you use each dose and whether dose adjustments may extend your treatment timeline. The Precision Peptide Genetic Test may help provide context regarding your predisposition to GLP-1 pathway sensitivity.

Understanding your genetic profile can support a more personalized conversation with your provider about dosing frequency and medication supply planning. Patients with certain genetic variants may require slower titration or lower maintenance doses, affecting how many doses you use from each opened pen. This insight should be interpreted alongside clinical response and provider guidance, not as a predictor of exact medication efficacy.

Signs Your Compounded Semaglutide Has Degraded and Should Be Discarded

Visual changes indicate degradation: discoloration, cloudiness, or visible particles in the solution warrant immediate discard. Compounded semaglutide should remain clear and colorless. Any off-odor or difficulty drawing medication from the pen may signal contamination or chemical breakdown.

If you notice reduced effectiveness—diminished appetite suppression or metabolic response compared to earlier doses from the same pen—degradation may be responsible. Never assume this is treatment failure without consulting your provider. Always cross-reference the opened date and storage conditions before attributing reduced response to your body's physiology.

How PlexusDx Supports a More Personalized Approach

PlexusDx's compounded semaglutide sourced from licensed 503A pharmacies is formulated with stability in mind, though each patient's handling and storage practices directly impact shelf life. Our pharmacy partners provide detailed storage instructions with every shipment. Genetic and biomarker insights may help your provider contextualize whether slower dose escalation affects your medication supply needs and overall treatment timeline.

The Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor and metabolic pathways, including variants in GLP1R and related genes. While genetics do not predict exact medication response or how quickly you progress through doses, they may provide context for why certain patients require longer titration schedules. This information should be interpreted with a qualified healthcare provider as part of your overall precision wellness strategy.

Understanding both your medication's stability window and your personalized genetic profile enables more informed conversations with your provider about supply planning, dosing cadence, and treatment continuity. PlexusDx supports this precision approach by offering compounded formulations alongside genetic testing, helping you and your provider make decisions grounded in both pharmacy science and individual predispositions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does the article give one expiry window that applies to every compounded pen?

No. It offers roughly 28 days after opening as a general figure, but says stability varies between compounding facilities depending on formulation and delivery mechanism, and that the dispensing pharmacy's written guidance governs. The article repeats that its own timeline assumes proper handling, so the beyond-use date printed by the pharmacy that filled the prescription is the number that actually applies.

What visual changes does the article say mean a pen should no longer be used?

It says compounded semaglutide should remain clear and colorless, and lists discoloration, cloudiness, or visible particles as reasons to stop using that pen. An off-odor or difficulty drawing the medication is described as a possible sign of contamination or chemical breakdown. The article directs patients to the dispensing pharmacy's instructions, and the pharmacy or prescriber should confirm what happens next.

If the effect seems weaker late in a pen, is that treatment failure?

Not necessarily, according to the article. It says diminished appetite suppression compared with earlier doses from the same pen can reflect degradation rather than the body's response, and warns against assuming treatment failure without consulting the provider. Its suggestion is to check the opened date and handling history first, before concluding that the medication itself has stopped working.

Are the potency percentages in the article's stability table reliable?

Treat them with caution. The table assigns a specific potency percentage to each week after opening, but the article gives no source for those figures and no stability testing behind them. What is defensible is its general point that potency declines gradually after opening; the exact percentages, and the claim that the product becomes unsafe past the window, are unsupported.

Why does the article say compounded shelf life differs from branded products?

Because each compounder's formulation and delivery mechanism differ, so the stability window is specific to the preparation rather than fixed across the category. The article says PlexusDx partners with licensed 503A pharmacies that provide detailed handling instructions with every shipment, and that what happens to the product after it arrives has a direct effect on how long it stays usable.

Related Reading

• Compounded Semaglutide 2
• Compounded Semaglutide
• Medvi Semaglutide
• Bioverse Semaglutide

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.